Protein Binding of Salicylate and Quinidine in Plasma from Patients with Renal Failure, Chronic Liver Disease and Chronic Respiratory Insufficiency

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1977 Mar 11

PMID 856605

Citations 11

Authors

M Perez-Mateo

S Erill

Affiliations

Soon will be listed here.

Abstract

The plasma protein binding of a representative acidic drug, salicylate, and a representative basic drug, quinidine, has been studied in patients with several diseases that are sometimes associated with uraemia or a change in serum albumin level. Decreased plasma protein binding of salicylate was observed in plasma from patients with uraemia and liver disease. Low albumin levels in these patients could only account inpart for the decreased binding. On the other hand, salicylate binding to plasma proteins appeared to be increased in patients with hypoxia. Decreased plasma protein binding of quinidine was observed in some patients with uraemia and in the majority of patients with liver disease.

Citing Articles

Plasma protein binding of azapropazone in patients with kidney and liver disease.

Jahnchen E, Blanck K, Breuing K, Gilfrich H, Meinertz T, Trenk D Br J Clin Pharmacol. 1981; 11(4):361-7.

PMID: 7259929 PMC: 1401678. DOI: 10.1111/j.1365-2125.1981.tb01133.x.

Altered quinidine disposition in a patient with chronic active hepatitis.

Powell J, Okada R, Conrad K, Guentert T, RIEGELMAN S Postgrad Med J. 1982; 58(676):82-4.

PMID: 7100030 PMC: 2426285. DOI: 10.1136/pgmj.58.676.82.

Clinical pharmacokinetics of quinidine.

Ochs H, Greenblatt D, Woo E Clin Pharmacokinet. 1980; 5(2):150-68.

PMID: 6988137 DOI: 10.2165/00003088-198005020-00003.

Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.

Netter P, Monot C, Stalars M, Mur J, Royer R, Faure G Eur J Drug Metab Pharmacokinet. 1984; 9(2):109-16.

PMID: 6745302 DOI: 10.1007/BF03189613.

Alteration of drug-protein binding in renal disease.

Reidenberg M, Drayer D Clin Pharmacokinet. 1984; 9 Suppl 1:18-26.

PMID: 6705423 DOI: 10.2165/00003088-198400091-00003.

References

Affrime M, Reidenberg M . The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol. 1975; 8(3-4):267-9. DOI: 10.1007/BF00567126. View

Lowenthal D, Briggs W, Levy G . Kinetics of salicylate elimination by anephric patients. J Clin Invest. 1974; 54(5):1221-6. PMC: 301669. DOI: 10.1172/JCI107865. View

Odar-Cederlof I, Lunde P, Sjoqvist F . Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet. 1970; 2(7677):831-2. DOI: 10.1016/s0140-6736(70)91506-0. View

CAMPION D . Decreased drug binding by serum albumin during renal failure. Toxicol Appl Pharmacol. 1973; 25(3):391-7. DOI: 10.1016/0041-008x(73)90312-8. View

Reidenberg M, Odar-Cederlof I, von Bahr C, Borga O, Sjoqvist F . Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971; 285(5):264-7. DOI: 10.1056/NEJM197107292850506. View

Nilsen O, Fremstad D, Jacobsen S . Increased binding of quinidine to serum albumin and lipoproteins in anuric rats. Eur J Pharmacol. 1975; 33(1):131-9. DOI: 10.1016/0014-2999(75)90147-8. View

Andreasen F . Protein binding of drugs in plasma from patients with acute renal failure. Acta Pharmacol Toxicol (Copenh). 1973; 32(6):417-29. DOI: 10.1111/j.1600-0773.1973.tb01488.x. View

Blum M, RIEGELMAN S, Becker C . Altered protein binding of diphenylhydantoin in uremic plasma. N Engl J Med. 1972; 286(2):109. DOI: 10.1056/NEJM197201132860224. View

Reidenberg M, Affrime M . Influence of disease on binding of drugs to plasma proteins. Ann N Y Acad Sci. 1973; 226:115-26. DOI: 10.1111/j.1749-6632.1973.tb20474.x. View

10.

ANTON A . The effect of disease, drugs, and dilution on the binding of sulfonamides in human plasma. Clin Pharmacol Ther. 1968; 9(5):561-7. DOI: 10.1002/cpt196895561. View

11.

Ebadi M, KUGEL R . Alteration in metabolism of acetylsalicylic acid in children with Down's syndrome: decreased plasma binding and formation of salicyluric acid. Pediatr Res. 1970; 4(2):187-93. DOI: 10.1203/00006450-197003000-00009. View

12.

Ghoneim M, Kramer E, Bannow R, Pandya H, ROUTH J . Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease. Anesthesiology. 1973; 39(4):410-5. DOI: 10.1097/00000542-197310000-00015. View

13.

Tsuchiya T, Levy G . Biotransformation of salicylic acid to its acyl and phenolic glucuronides in man. J Pharm Sci. 1972; 61(5):800-1. DOI: 10.1002/jps.2600610530. View

14.

Olsen G, Bennett W, Porter G . Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther. 1975; 17(6):677-84. DOI: 10.1002/cpt1975176677. View

15.

SCHOLTAN W . [The binding of long-acting sulfonamides on serum proteins. 2]. Arzneimittelforschung. 1961; 11:707-20. View

16.

Lunde P, Rane A, Yaffe S, Lund L, Sjoqvist F . Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther. 1970; 11(6):846-55. DOI: 10.1002/cpt1970116846. View

17.

ANTON A, Corey W . Interindividual differences in the protein binding of sulfonamides: the effect of disease and drugs. Acta Pharmacol Toxicol (Copenh). 1971; 29 Suppl 3:134-51. DOI: 10.1111/j.1600-0773.1971.tb03293.x. View

18.

Tikhonov V . [Serum protein binding of salicylates in chronic circulatory insufficiency]. Ter Arkh. 1972; 44(4):83-6. View

19.

Ehrnebo M, Odar-Cederlof I . Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients. Eur J Clin Pharmacol. 1975; 8(6):445-53. DOI: 10.1007/BF00562320. View

20.

Arango G, MAYBERRY W, Hockert T, ELVEBACK L . Total and free human serum thyroxine in normal and abnormal thyroid states. Mayo Clin Proc. 1968; 43(7):503-16. View